Print

HVTN 050/Merck 018

A Worldwide, Phase I, Dose-Escalating Study of the Safety, Tolerability, and Immunogenicity of a 3-Dose Regimen of the ?MRKAd5 HIV-1 gag Vaccine in Healthy Adults

Trial Details:

I Terminated
HIV Vaccine Trials Network (HVTN), Merck February 11, 2003
MRKAd5 HIV-1 gag Adeno 5 gag B
MRKAd5 HIV-1 gag Viral Vector - Adeno
Brazil, Dominican Republic, Haiti, Malawi, Peru, South Africa, Thailand, USA 435
http://www.hvtn.org